Basal cell carcinoma has low immunogenicity. Tumor cells express Foxc1 protein (red), which suppresses HLA class I (green) in the tumor cells. Compromised antigen presentation ranks among the top ...
Durable, ongoing near-complete response to nivolimab + relatlimab in a 64 year old with locally-advanced BCC after resistance to 26 wks of nivolimab alone. A new study led by researchers at the Johns ...
Epithelioma Treatment Market to reach USD 13.1 billion by 2035, driven by rising skin cancer cases and growing adoption of ...
Basal cell carcinoma (BCC) represents the most prevalent form of skin cancer, with research efforts increasingly focused on elucidating its molecular underpinnings and improving therapeutic strategies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback